Plasma concentration and eGFR in preterm and term neonates receiving gentamicin or successive amikacin therapy.
Bonifasius Siyuka SinguMilka Ndapandula NdeunyemaEne I EtteClarissa Hildegard PieperRoger Karel VerbeeckPublished in: BMC pediatrics (2023)
Although eGFR decreased significantly as a function of postnatal age in neonates receiving amikacin, the majority (91.4%) of these neonates were able to clear the drug to <ā5 mcg/mL within a 24-hour dosing interval.